Impel NeuroPharma Inc.

IMPL 4 | $0.2411 -77.19% 860K

(0.0% 1d) (0.0% 1m) (-77.2% 1y) (0.0% 2d) (10.1% 3d) (0.0% 7d) (-28.63% volume)
Earnings Calendar: 2024-03-22
Market Cap: $ 5,762,297
https://impelnp.com
Sec Filling | Patents | n/a employees

(US) Impel NeuroPharma, Inc. is a late-stage pharmaceutical company focused on utilizing its proprietary technology to develop and commercialize transformative therapies for people suffering from diseases with high unmet needs, with an initial focus on diseases of the CNS. The Company’s strategy is to rapidly advance its product candidate pipeline that pairs its proprietary Precision Olfactory Delivery (POD®) system with well-established therapeutics, including TRUDHESA™ for the acute treatment of migraine, INP105 for the acute treatment of agitation and aggression in patients with autism, and INP107 for OFF episodes in Parkinson’s disease.

parkinson treatment

add to watch list Paper trade email alert is off

Akoya Biosciences Inc

AKYA | $3.81 -1.04% -1.05% 170K

Professional, Scientific, and T...

(0.0% 1d) (-23.8% 1m) (-47.9% 1y) (0.0% 2d) (0.0% 3d) (-5.2% 7d) (-44.49% volume)
Earnings Calendar: 2024-03-04
Market Cap: $ 187,226,185
https://www.akoyabio.com
Sec Filling | Patents | n/a employees

As The Spatial Biology Company®, Akoya Biosciences’ mission is to bring context to the world of biology and human health through the power of spatial phenotyping. The company offers comprehensive single-cell imaging solutions that allow researchers to phenotype cells with spatial context and visualize how they organize and interact to influence disease progression and treatment response. Akoya offers two distinct solutions, the CODEX® and Phenoptics™ platforms, to serve the diverse needs of researchers across discovery, translational and clinical research.

t-cell treatment ceiling

add to watch list Paper trade email alert is off

Alzamend Neuro Inc

ALZN | $0.6894 -0.23% -0.23% 28K

Professional, Scientific, and T...

(0.0% 1d) (-35.2% 1m) (13.3% 1y) (-1.4% 2d) (-1.4% 3d) (-8.2% 7d) (3.58% volume)
Earnings Calendar: 2024-03-14
Market Cap: $ 4,734,004
https://alzamend.com/
Sec Filling | Patents | 3 employees

(United States) Alzamend Neuro is a preclinical stage biopharmaceutical company focused on developing novel products for the treatment of neurodegenerative diseases and psychiatric disorders, including Alzheimer’s disease. With its product candidates, the company aims to bring treatments or cures to market at a reasonable cost as quickly as possible. Its current pipeline consists of two novel therapeutic drug candidates, AL001 - a patented ionic cocrystal technology delivering a therapeutic combination of lithium, proline and salicylate, and AL002 - a patented method using a mutant-peptide sensitized cell as a cell-based therapeutic vaccine that seeks to restore the ability of a patient’s immunological system to combat Alzheimer’s. Both of its product candidates are licensed from the University of South Florida Research Foundation, Inc. pursuant to royalty-bearing exclusive worldwide licenses.

treatment msa vaccine t-cell lithium alzheimer neurodegenerative alzheimer’s

add to watch list Paper trade email alert is off

Biomea Fusion Inc

BMEA | $10.87 -2.6% -2.67% 1.3M

Professional, Scientific, and T...

(0.0% 1d) (-36.2% 1m) (-64.3% 1y) (0.0% 2d) (0.0% 3d) (-13.3% 7d) (114.15% volume)
Earnings Calendar: 2023-11-06
Market Cap: $ 390,117,343
https://www.biomeafusion.com
Sec Filling | Patents | 12 employees

Biomea Fusion, Inc. operates as a biopharmaceutical company. The Company focuseS on the discovery, development, and commercialization of irreversible small molecules to treat patients with genetically defined cancers. Biomea Fusion serves customers in the United States.

genetic cancer msa

add to watch list Paper trade email alert is off

Day One Biopharmaceuticals Inc

DAWN 4 | $14.98 -4.89% -5.14% 1.4M

Professional, Scientific, and T...

(0.0% 1d) (-0.7% 1m) (9.2% 1y) (0.0% 2d) (0.0% 3d) (8.0% 7d) (83.74% volume)
Earnings Calendar: 2024-03-04
Market Cap: $ 1,308,909,902
https://dayonebio.com
Sec Filling | Patents | 20 employees

(US) Day One Biopharmaceuticals is a clinical-stage biopharmaceutical company dedicated to developing and commercializing targeted therapies for patients of all ages with genomically defined cancers. Day One was founded to address a critical unmet need: children with cancer are being left behind in a cancer drug development revolution. Its name was inspired by the “The Day One Talk”1 that physicians have with patients and their families about an initial cancer diagnosis and treatment plan. The company aims to re-envision cancer drug development and redefine what’s possible for all people living with cancer—regardless of age—starting from Day One. Day One partners with leading clinical oncologists, families, and scientists to identify, acquire, and develop important emerging cancer treatments. The Company’s lead product candidate, DAY101, is an oral, highly-selective type II pan-RAF kinase inhibitor, and is being evaluated in a pivotal Phase 2 clinical trial (FIREFLY-1) in pediatric, adolescent and young adult patients with recurrent or progressive low-grade glioma (pLGG). The Company’s pipeline also includes the investigational agent pimasertib, a clinical-stage, oral, small molecule found to selectively inhibit mitogen-activated protein kinase kinases 1 and 2 (MEK). Through Day One and its collaborators, cancer drug development comes of age. Day One is based in South San Francisco.

treatment diagnostics cancer

add to watch list Paper trade email alert is off

Doximity Inc - Class A

DOCS | News | $24.63 -0.77% -0.12% 1.7M

Professional, Scientific, and T...

(0.0% 1d) (-12.1% 1m) (-32.4% 1y) (-1.6% 2d) (-1.6% 3d) (-3.1% 7d) (Infinity% volume)
Earnings Calendar:
Market Cap: $ 3,008,839,371
https://www.doximity.com
Sec Filling | Patents | 2021 employees

Founded in 2010, Doximity is the leading digital platform for U.S. medical professionals. The company's network members include over 80% of U.S. physicians across all specialties and practice areas. Doximity provides its verified clinical membership with digital tools built for medicine, enabling them to collaborate with colleagues, stay up to date with the latest medical news and research, manage their careers and conduct virtual patient visits. Doximity's mission is to help doctors be more productive so they can provide better health care for their patients.

urea

add to watch list Paper trade email alert is off

Finch Therapeutics Group Inc

FNCH | $2.205 -6.57% -7.03% 30K

Professional, Scientific, and T...

(0.0% 1d) (-14.2% 1m) (-84.3% 1y) (0.0% 2d) (-11.1% 3d) (-0.2% 7d) (-76.8% volume)
Earnings Calendar: 2023-03-30
Market Cap: $ 3,540,707
https://finchtherapeutics.com
Sec Filling | Patents | n/a employees

Finch Therapeutics is a clinical-stage microbiome therapeutics company leveraging its Human-First Discovery® platform to develop a novel class of orally administered biological drugs. With the capabilities to develop both complete and targeted microbiome therapeutics, Finch is advancing a rich pipeline of candidates designed to address a wide range of unmet medical needs. Finch’s lead candidate, CP101, is in late-stage clinical development for the prevention of recurrent C. difficile infection (CDI), and has received Breakthrough Therapy and Fast Track designations from the U.S. Food and Drug Administration. In June 2020, Finch announced that CP101 met its primary efficacy endpoint in PRISM3, the first of two pivotal trials to support the development of CP101 for the prevention of recurrent CDI. Finch plans to initiate a Phase 3 trial, referred to as PRISM4, as its second pivotal trial of CP101 for recurrent CDI. Finch is also developing CP101 for the treatment of chronic hepatitis B virus, and FIN-211 for the treatment of the gastrointestinal and behavioral symptoms of autism spectrum disorder. In partnership with Takeda, Finch is advancing FIN-524 and FIN-525 for the treatment of ulcerative colitis and Crohn’s disease, respectively.

hepatitis gastrointestinal treatment injection

add to watch list Paper trade email alert is off

Monte Rosa Therapeutics Inc

GLUE | $5.84 -1.35% -1.37% 110K

Professional, Scientific, and T...

(0.0% 1d) (-22.9% 1m) (2.3% 1y) (0.0% 2d) (0.9% 3d) (-11.0% 7d) (5.5% volume)
Earnings Calendar: 2024-03-14
Market Cap: $ 292,876,000
https://www.monterosatx.com
Sec Filling | Patents | 60 employees

Monte Rosa Therapeutics is a biotechnology company discovering and developing molecular glues to degrade disease-causing proteins. The company has created a platform to rationally design small molecules that reprogram ubiquitin ligases to eliminate disease drivers previously deemed undruggable. The company’s drug discovery platform combines diverse and proprietary chemical libraries of small molecule protein degraders with in-house proteomics, structural biology, machine learning-based target selection and computational chemistry capabilities to predict and obtain protein degradation profiles. Monte Rosa was launched from founding investor Versant Ventures’ Ridgeline Discovery Engine and is headquartered in Boston, Mass., with research operations in both Boston and Basel, Switzerland.

drug discovery profitable computational machine learning

add to watch list Paper trade email alert is off

Century Therapeutics Inc

IPSC | $3.06 2.86% 2.78% 110K

Professional, Scientific, and T...

(0.0% 1d) (-35.4% 1m) (1.6% 1y) (0.0% 2d) (8.8% 3d) (-15.8% 7d) (-37.1% volume)
Earnings Calendar: 2024-03-14
Market Cap: $ 198,342,661
https://www.centurytx.com/
Sec Filling | Patents | 102 employees

(US) Century Therapeutics, Inc. specializes in adult stem cells to develop curative cell therapy products for cancer that overcome the limitations of first generation cell therapies as well as provides testing and research services.

t-cell cancer

add to watch list Paper trade email alert is off

iSpecimen Inc

ISPC | $0.2915 -30.76% -44.43% 2.8M

Professional, Scientific, and T...

(0.0% 1d) (5.5% 1m) (-83.3% 1y) (0.0% 2d) (38.1% 3d) (37.4% 7d) (948.27% volume)
Earnings Calendar: 2024-02-21
Market Cap: $ 2,732,721

Sec Filling | Patents | 75 employees

headquartered in lexington, ma, ispecimen is the marketplace for human biospecimens, providing researchers with the specimens they need from the patients they want. the privately held company has developed the ispecimen marketplace, an online platform connecting healthcare organizations that have access to patients and specimens with the scientists who need them. proprietary, cloud-based technology enables researchers to intuitively search for specimens and patients across a federated partner network of hospitals, labs, biobanks, blood centers, and other healthcare organizations. researchers easily and compliantly gain access to specimens to drive scientific discovery. partner sites gain an opportunity to contribute to biomedical discovery as well as their bottom line. and ultimately, healthcare advances for all.

add to watch list Paper trade email alert is off

Janux Therapeutics Inc

JANX | $48.69 -0.33% -0.33% 670K

Professional, Scientific, and T...

(0.0% 1d) (22.2% 1m) (216.0% 1y) (0.0% 2d) (1.5% 3d) (-6.1% 7d) (8.98% volume)
Earnings Calendar: 2024-03-08
Market Cap: $ 2,515,328,321
https://www.januxrx.com
Sec Filling | Patents | 16 employees

(US) Janux Therapeutics is developing safe, effective novel immunotherapies with the company’s proprietary TRACTr technology. Janux’s TRACTr technology employs a modular design to rapidly engineer drug candidates against specific targets. The Janux TRACTr development pipeline targets multiple solid tumor indications, including colorectal, gastroesophageal, prostrate, NSCLC, triple negative breast, and ovarian cancers. Janux technology can be applied to immunotherapies that target all three stages of an anti-tumor immune response. Combining Janux’s tumor-specific activation with multi-stage anti-tumor signaling has the potential to significantly improve safety, expand the therapeutic dosing window, and maximize patient responses. Janux was founded in the Avalon Ventures accelerator, COI Pharmaceuticals, Inc., in San Diego.

cancer ovarian cancer

add to watch list Paper trade email alert is off